Ipca Labs Q1 Results FY27: Net Profit Surges 80.36%, Revenue Rs 2788 crore
- August 14, 2026
- Posted by: Ankit Jaiswal
- Category: Market
Ipca Labs Q1 results: Revenue Rs 2788 crore (+20.76% YoY). PAT Rs 422 Cr (+80.36% YoY). GP Rs 558 crore. CMP Rs 1796.3 (+1.68%).
Quick Answer
Ipca Labs Q1 results for FY27, declared on August 13, 2026, show revenue of Rs 2788 crore, up 20.76% year on year from Rs 2308 crore. Net profit came in at Rs 422 crore, up 80.36% year on year on a consolidated basis. Gross profit stood at Rs 558 crore for the April to June 2026 quarter. The stock closed at Rs 1796.3, up 1.68% on results day.
Ipca Labs Q1 results for FY27 were declared on August 13, 2026, covering the April to June 2026 quarter. Revenue came in at Rs 2788 crore, up 20.76% year on year from Rs 2308 crore. Net profit stood at Rs 422 crore on a consolidated basis. Gross profit was Rs 558 crore for the quarter.
The Ipca Labs Q1 results analysis below covers financial highlights, key business drivers, FY27 outlook, and investor risks. The Nifty Pharma index reflects the broader Pharmaceuticals sector backdrop against which these results should be read.
Click Here – Get Free Investment Predictions
Ipca Labs Q1 Results: Financial Highlights
| Metric | Q1 FY27 (Jun 26) | Q1 FY26 (Jun 25) | YoY Change |
|---|---|---|---|
| Revenue | Rs 2788 Cr | Rs 2308 Cr | +20.76% YoY |
| Gross Profit | Rs 558 Cr | Rs 316 Cr | +76.60% YoY |
| Net Profit (PAT) | Rs 422 Cr | Rs 234 Cr | +80.36% YoY |
Source: Company filing, August 13, 2026. Figures in Rs Crore. Consolidated basis.
Q1 FY27 Performance Analysis
Ipca Labs Q1 results show revenue that grew strongly during the April to June 2026 period. Gross profit improved, pointing to better cost management during the quarter. Net profit of Rs 422 crore reflects a healthy earnings trajectory.
A detailed look at Ipca Labs Q1 results reveals that revenue grew 20.76% year on year, while the consolidated numbers offer a group-level view of the company. Analysts will focus on margin trajectory and the outlook for the remaining quarters of FY27.
Investors assessing these quarterly results should also track working capital trends, operating leverage, and management commentary on FY27 guidance. Subsequent quarterly disclosures will help validate whether the trends visible in this print continue.
Check Live Financials on the Univest Screener
Key Business Factors This Quarter
Domestic Formulations Volume — This was a key driver this quarter. Its positive contribution supported the quarterly revenue trajectory. Investors should track changes in this area in subsequent disclosures.
Export Revenue and US Market — This had a direct bearing on gross margins during the April to June 2026 period. Favourable movement here helped support the quarterly gross profit level. Management’s approach will shape margin outcomes in the quarters ahead.
Active Pharmaceutical Ingredient Mix — This factor shaped the overall operating environment this quarter. Monitoring its trajectory will help investors anticipate directional changes in the next quarterly update.
Dividend Details
No interim dividend was announced as part of the quarterly results declared on August 13, 2026 for Ipca Labs. Companies in the Pharmaceuticals sector typically declare dividends once a year alongside full-year results. Investors should monitor official BSE or NSE filings for any future payout updates.
FY27 Outlook for Ipca Labs
Ipca Labs Q1 results for FY27 establish a positive starting point for FY27. The Pharmaceuticals sector broadly faces steady conditions heading into H2 FY27, providing context for interpreting the April to June quarter print.
Investors using these Q1 FY27 results as a base for full-year projections should monitor whether revenue momentum and margin improvement continue into Q2 and Q3. Management commentary on capacity, order book, and pricing will be important inputs for refining full-year estimates.
Ipca Labs Stock Performance After Q1 Results
Ipca Labs’s share price closed up at Rs 1796.3, up 1.68% on August 13, 2026, the day the Q1 FY27 results were announced. The market received the results constructively. Stock movements on results day reflect immediate sentiment and may not represent the long-term investment picture.
Investors can track live price data and financial details on NSE (nseindia.com) and BSE (bseindia.com). Always verify current prices and official filings before any investment decision.
Download the Univest iOS App or Univest Android App to track Ipca Labs’s live share price.
Key Risks to Watch After the Q1 Results
US FDA Regulatory Risk
This risk could weigh on revenue or margins if it intensifies. Investors should track how management addresses this in upcoming quarterly disclosures.
Generic Pricing Pressure
This represents a potential headwind for FY27. If it materialises, it could affect the earnings trajectory visible in recent quarterly numbers.
API Cost Volatility
This structural risk is shared with peers in the Pharmaceuticals space. It warrants monitoring as it can influence fair value and longer-term earnings potential.
Conclusion
Ipca Labs Q1 results for FY27 present a broadly strong picture. Revenue of Rs 2788 crore and net profit of Rs 422 crore indicate the business is gaining momentum in the Pharmaceuticals space. Investors should track the next two quarters alongside the Ipca Labs Q1 results baseline as FY27 progresses. Always consult a SEBI-registered investment advisor before any portfolio decision.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions on Ipca Labs Q1 Results
What were Ipca Labs Q1 results for FY27?
Ans. Ipca Labs Q1 results for FY27 show revenue of Rs 2788 crore, up 20.76% year on year from Rs 2308 crore and net profit of Rs 422 crore on a consolidated basis. Declared August 13, 2026.
When were the Q1 FY27 results declared for Ipca Labs?
Ans. The Q1 FY27 results for Ipca Labs were declared on August 13, 2026, covering the April to June 2026 quarter on a consolidated basis.
What was the revenue in Q1 FY27?
Ans. Revenue for the quarter was Rs 2788 crore, up 20.76% year on year from Rs 2308 crore. Refer to official BSE or NSE filings for complete financial data.
Did Ipca Labs Q1 results include a dividend?
Ans. No interim dividend was included in the Q1 FY27 results announcement for Ipca Labs. Dividends are typically declared with full-year results. Check official filings for updates.
How did the stock react to Q1 FY27 results?
Ans. The stock closed up at Rs 1796.3, up 1.68% on August 13, 2026. Stock movements on results day reflect immediate sentiment and may not indicate long-term direction.
What are the key risks highlighted after Q1 FY27?
Ans. Key risks after Q1 FY27 include us fda regulatory risk, generic pricing pressure, and api cost volatility. Track quarterly disclosures for updates on how these evolve.
What is the FY27 outlook based on Q1 FY27 performance?
Ans. Based on Q1 FY27 performance, FY27 full-year results will depend on sustaining revenue growth and expanding margins. The Pharmaceuticals sector environment and company execution will be the main drivers.
Where can I find the complete Q1 FY27 financial data for Ipca Labs?
Ans. Ipca Labs Q1 results are available on BSE (bseindia.com) and NSE (nseindia.com) filing portals. The Univest screener also provides a curated financial snapshot.
